PDCD1 and non-small cell lung carcinoma: According to a meta-analysis in NSCLC patients ≥75 years who participated in four randomized studies (CheckMate 057, KEYNOTE-010, OAK, or POPLAR) [25,27,28,29], mOS in patients receiving PD-1/PD-L1 blocking antibodies versus docetaxel was 14.7 versus 9.5 months [30].